Subject is ≥ 18 years at the time of signing informed consent;
Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
Presence of measurable or evaluable disease;
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
Contraceptives or other approved avoidance of pregnancy measures
You may not be if
Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
Undergone major surgery ≤ 2 weeks prior to starting study drug;
Evidence of mucosal or internal bleeding;
Impaired cardiac function or conduction defect;
Concurrent severe and/or uncontrolled medical conditions
Clareo Health | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
